## **PATENT APPLICATION**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	) : Examiner: Not Yet Assigned
MEGUMI TAKEUCHI, ET AL.	) : Group Art Unit: Not Yet Assigned
Application No.: 10/587,264	)
I.A. Filing Date: January 28, 2005	; )
For: AGENTS FOR TREATING MIGRAINE	) : October 24, 2006

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the documents listed in the "Foreign Patent Documents" and "Other Document(s)" are also enclosed.

Documents A-D, M and O-P were cited in a Written Opinion, a copy of which is enclosed as well. Documents Q-T were cited at specification page 1, and documents E-L and N were cited at specification page 3. Their relevance is discussed therein.

Also, for the Examiner's convenience, the chart below shows where the other documents were cited and their family member equivalents.

Document No.	Family-Member Equivalent	Cited in
JP 60-174788	4,599,338	Written Opinion
JP 6-211856	5,484,920	Written Opinion
WO 92/06976	5,756,735	Written Opinion
JP 2002-512246	6,187,780	Written Opinion
JP 26516/1972	3,641,010	Specification page 3
JP 211856/1994	5,484,920	Specification page 3
JP 239862/1994	5,670,498	Specification page 3
WO 92/06976	5,756,735	Specification page 3
WO 94/01114	5,543,415	Specification page 3
WO 95/23165	6,245,900	Specification page 3
WO 99/12546	6,727,259	Specification page 3
WO 99/35147	6,579,868	Specification page 3
JP 11-508267	WO 97/01551	Written Opinion
JP 16559/1994	0 565 377	Specification page 3

## **CONCLUSION**

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Attorney for Applicants Registration No.: 31,865

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New York, New York 10112-3800 Facsimile: (212) 218-2200

LSP\ac

FORM PTO 1449 (modified)		ATTY DOCKET NO.	APPLICATION NO.					
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE PE				00005.001299	10/587,264			
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		APPLICANT  Megumi Takeuchi, et al.						
l act a c 2000 l			I.A. FILING DATE <b>January 28, 2005</b>	GROUP Not Yet Assigned				
			193	8/	U.S. PATENT DOCUMENTS			
*EXAMI NER INITIAL		DOCUMENT NUMBER	DATE DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	Α	4,599,338	7/86		Regnier et al	514	265	
	В	5,484,920	1/96	Suzuki et al			268	
	С	5,756,735	5/98	Suzuki et al			267	
	D	6,187,780	2/01	Blech et al			263	
	E	3,641,010	2/72		Schweiss et al	260	240	
	F	5,484,920	1/96		Suzuki et al	544	268	
	G	5,670,498	9/97	Suzuki et al			212	
	Н	5,756,735	5/98	Suzuki et al			267	
	ı	5,543,415	8/96		Suzuki et al	514	263	
	J	6,245,900	6/01		Yamasaki et al	530	402	
	κ	6,727,259	4/04		Shimada et al	514	263.34	
	L	6,579,868	6/03		Asano et al	514	211.08	
				FO	REIGN PATENT DOCUMENTS	1		
		DOCUMENT NUMBER	DATE		COUNTRY .	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
	M	WO 97/01551	1/97		PCT			
	N	0 565 377	8/93		EPO			
			OTHER DOCUM	MENT(S)	(Including Author, Title, Date, Pertinent Pages, Etc.)			
	O Villalón, et al., "Effects of S9977 and dihydroergotamine in an animal experimental model for migraine", <i>Pharmacological Research</i> (1992), Vol. 25, No. 2, pp. 125-137							
	Р	Guieu, et al., "Ad	enosine and	migra	aine", <i>Can. J. Neurol. Sci.</i> (1998), Vo	l. 25, N	o. 1, pp. 55	-58
	Q Ngai, et al., "Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles", Am J Physiol Heart Circ Physiol (2001), Vol. 280, p. H2329-H2335							
EXAMINER	KAMINER DATE CONSIDERED							

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)		ATTY DOCKET NO. APPLICATION NO.						
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			00005.001299	10/587,264				
		OF REFERENCES CITED BY (Use several sheets if nece	APPLICANT(S)		APPLICANT Megumi Takeuchi, et al.			
			I.A. FILING DATE  January 28, 2005	GROUP Not Yet Assigned				
U.S. PATENT DOCUMENTS								
*EXAMI NER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	S SUBCLASS	FILING DATE IF APPROPRIATE
	-							
	-							
		T	r	FO	REIGN PATENT DOCUMENTS	Т		
!		DOCUMENT NUMBER	DATE		COUNTRY		S SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
	_							
,								
	_							
		T			) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	R	Honey, et al., "Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat", <i>Cephalalgia</i> (2002), Vol. 22, p. 260-264						
	s	Erickson, et al, "1,3,8-Trisubstituted Xanthines. Effects of substitution pattern upon adenosine receptor A <sub>1</sub> /A <sub>2</sub> affinity", <i>J. Med. Chem.</i> , (1991), Vol. 34, p. 1431-1435						
	Т	Jacobson, et al., "Structure-activity relationships of 8-styrylxanthines as A <sub>2</sub> -selective adenosine antagonists", <i>J. Med. Chem.</i> (1993), Vol. 36, p. 1333-1342						
EXAMINER	 R				DATE CONSIDERED			

Sheet 2 of 2

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.